” …significant reduction in the Kupperman index following 12 weeks of treatment, which was sustained throughout the 12 months of treatment.”

Efficacy and safety of standard versus low-dose Femarelle (DT56a) for the treatment of menopausal symptoms.

RESULTS:
In both groups there was a significant reduction in the Kupperman index following 12 weeks
of treatment, which was sustained throughout the 12 months of treatment (p < 0.01).
Seventy-six percent of the patients in the SD group reported a decrease in vasomotor
symptoms and seventy-eight % in the LD group (NS). This decrease was sustained following
12 months of treatment. There was no change in TSH and sex hormone levels or endometrial
thickness during the study period.

Read More>>>